Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen to Report Fourth Quarter and Full Year 2018 Financial Results
WALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on Thursday, February 21, 2019. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2018. The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers.
external link icon
Repligen to Report Third Quarter 2018 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter of 2018 financial results on Thursday, November 1, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2018. 

The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the
external link icon
Repligen to Report Second Quarter 2018 Financial Results
WALTHAM, Mass., July 19, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter of 2018 financial results on Thursday, August 2, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six-month reporting periods ended June 30, 2018. The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must
external link icon
Repligen Reports First Quarter 2018 Financial Results
Record quarterly revenue of $44.8M represents 46% year-over-year growth Revenue guidance raised to $182-$188 million for full year 2018 WALTHAM, Mass., May 08, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2018. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2018 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We had a strong start to the year led by sales of our direct filtration and chromatography products, which were up by over 90% year-on-year. This includes our Spectrum business, which continues to outperform our expectations. We are also excited about the depth of our R&D pipeline which is generating new products, including our recently launched OPUS 80R pre-packed columns
external link icon
Repligen to Report First Quarter 2018 Financial Results
WALTHAM, Mass., April 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter of 2018 financial results on Tuesday, May 8, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2018.
The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide
external link icon
Repligen to Report Fourth Quarter and Full Year 2017 Financial Results
WALTHAM, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three and twelve-month reporting periods ended December 31, 2017. The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay
external link icon
Repligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the Investor Events section of Company's website. A replay of this webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen Reports First Quarter 2014 Financial Results
- Product Revenue Increases 20% to a Record $14.3 Million - - Net Income Increases 83% to $4.3 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 8, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the first quarter ended March 31, 2014. Below are the Company's financial and business highlights for the quarter as well as financial guidance for the year 2014. Also included is access information for today's webcast and conference call. Financial Highlights: Bioprocessing product revenue for the first quarter of 2014 was $14.3 million, an increase of approximately 20% over the first quarter of 2013. Bioprocessing product gross profit margin was 55.8% for the first quarter of 2014, compared to 42.2% for the 2013 period. Total revenue for the first quarter of 2014 was $16.3 million compared to $16.5 million in 2013. Net income was $4.3 million for the first quarter of 2014 compared to $2.3 million in 2013;
corporate icon
ATMP
Advanced Therapy Medical Products (ATMP) have immense potential to transform the lives of patients with genetic diseases. Repligen partners with developers and manufacturers, providing technology breakthroughs and high impact solutions for plasmid and viral vector development and manufacturing.
corporate icon
Antibody Drug Conjugates
Antibody-drug conjugates (ADC) represent a breakthrough in targeted cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. By delivering powerful treatments directly to cancer cells, ADCs provide an alternative solution that enhances efficacy and minimizes side effects.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support